DOCU vs SGMT · P/E 15, rev $2.98B vs rev $2.0M
DocuSign Inc (DOCU) versus Sagimet Biosciences Inc. Series A Common Stock (SGMT) — a side-by-side from cached financials, not a winner call.
DocuSign Inc (DOCU) is a software - application company listed on US.
Sagimet Biosciences Inc. Series A Common Stock (SGMT) is a biotechnology company listed on NASDAQ.
Latest reported DOCU revenue for 2025-01-31 was $2.98B. Net income was $1.07B. Revenue was up 7.8% from 2024-01-31 to 2025-01-31. DOCU currently screens at market cap $15.74B and trailing P/E 14.8.
Latest reported SGMT revenue for 2023-09-30 was $2.0M. Net income was -$6.4M. Revenue was up 0.0% from 2023-07-31 to 2023-09-30. SGMT currently screens at market cap $403.2M.
DOCU currently screens at market cap $15.74B and trailing P/E 14.8. SGMT currently screens at market cap $403.2M.
Not investment advice. Open the DOCU and SGMT stock pages for the full models.
Not investment advice.